Related Experiment Video
Updated: Sep 28, 2026

A Three-dimensional Model of Spheroids to Study Colon Cancer Stem Cells
Published on: January 22, 2021
Expression of G1-S modulators (p53, p16, p27, cyclin D1, Rb) and Smad4/Dpc4 in intrahepatic cholangiocarcinoma
Yun Kyung Kang1, Woo Ho Kim, Ja June Jang
1Department of Pathology, Inje University Seoul Paik Hospital and Seoul National University College of Medicine, Korea.
Abstract:
Aberrations of G1-S cell cycle arrest and TGF-beta/Smad pathway are critical events in human carcinogenesis. We studied alterations of both pathways by immunohistochemical staining for p53, p16, p27, cyclin D1, Rb and Smad4/Dpc4 in 42 intrahepatic cholangiocarcinomas (ICCs). Abnormal nuclear overexpression of p53 and cyclin D1 was noted in 15 (35.7%) and 26 (61.9%) cases, respectively. Total loss of p16, p27, Rb and Smad4 was detected in 15 (35.7%), 13 (31.0%), 5 (11.9%) and 19 (45.2%) cases, respectively. Forty cases (95.2%) showed aberrations of at least one of the pathways, of which 21 (50%) revealed abnormality in G1-S pathway only, 17 (40.5%) had abnormalities in both pathways and 2 (4.8%) had an abnormality in TGF-beta/Smad pathway only. Among the examined genes, loss of Smad4 was found to have a positive relationship with the pTNM stage (P < 0.05). The overall stage of the high-altered group (alterations in 2 to 5 of the genes, n = 29) was significantly higher than that of the low-altered group (alteration of one or no gene, n = 13) (P < 0.01). We also examined the expression of above genes in the accompanying biliary dysplasia and found out abnormal expression of p53, cyclin D1 or p16 in 7 out of 13 dysplastic lesions. Our data suggest that abnormal G1-S cell cycle and altered TGF-beta/Smad pathway are major events in cholangiocarcinogenesis. Moreover, there might be a possible cumulative effect of the alterations in the examined genes upon the clinical outcome of patients with resectable ICCs.
Insights
Aberrations in the G1-S cell cycle arrest and TGF-beta/Smad pathways are key to human cancer development. These alterations are frequent in intrahepatic cholangiocarcinomas and correlate with advanced disease stages.
Area of Science:
- Oncology
- Molecular Biology
- Gastroenterology
Background:
- Aberrations in cell cycle regulation (G1-S arrest) and the TGF-beta/Smad pathway are implicated in human carcinogenesis.
- Intrahepatic cholangiocarcinoma (ICC) is a complex malignancy where these pathways may play a significant role.
Purpose of the Study:
- To investigate the alterations in G1-S cell cycle arrest and TGF-beta/Smad pathways in intrahepatic cholangiocarcinomas (ICCs).
- To correlate these molecular changes with clinicopathological features and disease progression.
Main Methods:
- Immunohistochemical staining was performed on 42 ICC tissue samples to assess the expression of p53, p16, p27, cyclin D1, Rb, and Smad4.
- Analysis included evaluation of adjacent biliary dysplasia for similar molecular alterations.
Main Results:
- High frequencies of abnormalities were observed: p53 (35.7%), cyclin D1 (61.9%), p16 loss (35.7%), p27 loss (31.0%), Rb loss (11.9%), and Smad4 loss (45.2%).
- Ninety-five percent of ICCs exhibited alterations in at least one pathway, with 50% showing G1-S pathway abnormalities only, 40.5% in both, and 4.8% in TGF-beta/Smad only.
- Loss of Smad4 correlated with advanced pTNM stage (P < 0.05).
- A higher number of gene alterations (2-5) was associated with significantly higher tumor stage (P < 0.01).
- Abnormal expression of p53, cyclin D1, or p16 was found in 7 of 13 dysplastic lesions.
Conclusions:
- Altered G1-S cell cycle regulation and TGF-beta/Smad signaling are critical events in cholangiocarcinogenesis.
- A cumulative effect of these molecular alterations may influence the clinical outcome in patients with resectable ICCs.
Related Concept Videos
Inhibition of Cdk Activity
Abnormal Proliferation
Negative Regulator Molecules
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
